Literature DB >> 23180593

Vasoactive exposures during pregnancy and risk of microtia.

Carla M Van Bennekom1, Allen A Mitchell, Cynthia A Moore, Martha M Werler.   

Abstract

BACKGROUND: Little is known about the etiology of nonsyndromic microtia. This study investigated the hypothesis that microtia is caused by vascular disruption.
METHODS: The study analyzed data from the population-based National Birth Defects Prevention Study (NBDPS) for deliveries between 1997 and 2005. Four hundred eleven nonsyndromic cases of microtia, with or without additional defects, were compared to 6560 nonmalformed infants with respect to maternal exposures to vasoactive medications and smoking during the periconceptional period and conditions that have previously been associated with vascular events (multiple gestation, maternal history of type 1, type 2, or gestational diabetes, and hypertension). Odds ratios (ORs) were estimated with multivariable models, controlling for the effects of race/ethnicity, education, periconceptional folic acid use, and study center.
RESULTS: Risk estimates for vasoactive medications and smoking were not meaningfully increased. Maternal type 1/2 diabetes was diagnosed before or during the index pregnancy in 4% and 1% of cases, respectively, compared to 1% and 0.05% of controls; the adjusted OR for these two groups combined was 7.2 (95% confidence interval [CI], 3.9-13.1). Gestational diabetes was observed for 9% of cases and 6% of controls; the OR was moderately elevated (OR, 1.4; 95% CI, 0.9-2.0). ORs were also increased for multiple gestations (OR, 2.5; 95% CI, 1.5-4.2) and pre-existing hypertension (OR, 1.6; 95% CI, 1.0-2.5).
CONCLUSIONS: Because ORs were only elevated for diabetes and not for vasoactive exposures or other potential vascular events, findings suggest that some microtia occurrences may be part of the diabetic embryopathy rather than manifestations of vascular disruption. Birth Defects Research (Part A), 2013. © 2012 Wiley Periodicals, Inc.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180593      PMCID: PMC4521508          DOI: 10.1002/bdra.23101

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  47 in total

1.  Infants of diabetic mothers are at increased risk for the oculo-auriculo-vertebral sequence: A case-based and case-control approach.

Authors:  Raymond Wang; Maria Luísa Martínez-Frías; John M Graham
Journal:  J Pediatr       Date:  2002-11       Impact factor: 4.406

2.  Is hemifacial microsomia linked to multiple maternities?

Authors:  K Lawson; N Waterhouse; D T Gault; M L Calvert; M Botma; R Ng
Journal:  Br J Plast Surg       Date:  2002-09

3.  Fetal vascular disruptions: mechanisms and some resulting birth defects.

Authors:  M I Van Allen
Journal:  Pediatr Ann       Date:  1981-06       Impact factor: 1.132

4.  Guidelines for case classification for the National Birth Defects Prevention Study.

Authors:  Sonja A Rasmussen; Richard S Olney; Lewis B Holmes; Angela E Lin; Kim M Keppler-Noreuil; Cynthia A Moore
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-03

5.  Vascular etiology of disruptive structural defects in monozygotic twins.

Authors:  H E Hoyme; M C Higginbottom; K L Jones
Journal:  Pediatrics       Date:  1981-02       Impact factor: 7.124

6.  Fetal ear malformations induced by maternal ingestion of thalidomide in the bonnet monkey (Macaca radiata).

Authors:  L M Newman; A G Hendrickx
Journal:  Teratology       Date:  1981-06

7.  Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia.

Authors:  Martha M Werler; Jane E Sheehan; Allen A Mitchell
Journal:  Epidemiology       Date:  2003-05       Impact factor: 4.822

8.  Retinoic acid embryopathy.

Authors:  E J Lammer; D T Chen; R M Hoar; N D Agnish; P J Benke; J T Braun; C J Curry; P M Fernhoff; A W Grix; I T Lott
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

9.  Risks of anticoagulant therapy in pregnant women with artificial heart valves.

Authors:  I Iturbe-Alessio; M C Fonseca; O Mutchinik; M A Santos; A Zajarías; E Salazar
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

10.  Vasoactive exposures, vascular events, and hemifacial microsomia.

Authors:  Martha M Werler; Jane E Sheehan; Catherine Hayes; Allen A Mitchell; John B Mulliken
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2004-06
View more
  5 in total

1.  Evaluation of prenatal diabetes mellitus and other risk factors for craniofacial microsomia.

Authors:  Babette Siebold; Carrie L Heike; Brian G Leroux; Matthew L Speltz; Amelia F Drake; Alexis L Johns; Kathleen A Kapp-Simon; Leanne Magee; Daniela V Luquetti
Journal:  Birth Defects Res       Date:  2019-03-30       Impact factor: 2.344

2.  Sociodemographic, health behavioral, and clinical risk factors for anotia/microtia in a population-based case-control study.

Authors:  Marisa A Ryan; Andrew F Olshan; Mark A Canfield; Adrienne T Hoyt; Angela E Scheuerle; Suzan L Carmichael; Gary M Shaw; Martha M Werler; Sarah C Fisher; Tania A Desrosiers
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-03-23       Impact factor: 1.675

Review 3.  Pre-pregnancy Obesity as a Modifier of Gestational Diabetes and Birth Defects Associations: A Systematic Review.

Authors:  Aimee S Parnell; Adolfo Correa; E Albert Reece
Journal:  Matern Child Health J       Date:  2017-05

4.  Risk factors and demographics for microtia in South America: a case-control analysis.

Authors:  Daniela V Luquetti; Babette S Saltzman; Jorge Lopez-Camelo; Maria da Graça Dutra; Eduardo E Castilla
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-11

5.  Genome-wide association study identifies multiple susceptibility loci for craniofacial microsomia.

Authors:  Yong-Biao Zhang; Jintian Hu; Jiao Zhang; Xu Zhou; Xin Li; Chaohao Gu; Tun Liu; Yangchun Xie; Jiqiang Liu; Mingliang Gu; Panpan Wang; Tingting Wu; Jin Qian; Yue Wang; Xiaoqun Dong; Jun Yu; Qingguo Zhang
Journal:  Nat Commun       Date:  2016-02-08       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.